Evotec SE logo

Evotec SENASDAQ: EVO

Profile

Sector:

Healthcare

Country:

Germany

IPO:

05 February 2004

Next earnings report:

29 August 2024

Last dividends:

N/A

Next dividends:

N/A
$1.66 B
-80%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
46%vs. sector
-85%vs. 3y high
37%vs. sector

Price

after hours | Fri, 28 Jun 2024 22:26:14 GMT
$4.69+$0.12(+2.63%)

Dividend

No data over the past 3 years
$226.72 M$225.87 M
$226.72 M-$22.45 M

Analysts recommendations

Institutional Ownership

EVO Latest News

Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
Accesswire15 May 2024 Sentiment: POSITIVE

Evotec SE, listed on the Frankfurt Stock Exchange and NASDAQ, will release its financial results for the first quarter of 2024 on May 22, 2024. A conference call will be held to discuss the results and give an update on the company's performance.

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Accesswire17 April 2024 Sentiment: POSITIVE

Evotec SE will release its financial results for 2023 on April 24, 2024, and will hold a conference call to discuss the results and provide an update on its performance.

Evotec SE (EVO) Business Update Conference Call (Transcript)
Seeking Alpha22 January 2024 Sentiment: NEUTRAL

Evotec SE (EVO) Business Update Conference Call (Transcript)

Evotec SE: Invitation to Conference Call
Accesswire22 January 2024 Sentiment: POSITIVE

HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec's Supervisory Board, Prof.

Why Is Evotec (EVO) Stock Down 12% Today?
InvestorPlace04 January 2024 Sentiment: NEGATIVE

Evotec (NASDAQ: EVO ) stock is falling on Thursday after the drug discovery and development partner announced the resignation of CEO Dr. Werner Lanthaler. According to a press release from the company, Lanthaler departure is immediate and won't see him finish his term as leader of the company.

Evotec SE (EVO) Q3 2023 Earnings Call Transcript
Seeking Alpha11 November 2023 Sentiment: POSITIVE

Evotec SE (NASDAQ:EVO ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Kirsty Ross-Stewart - Citi Charles Weston - RBC Capital Markets Pippa Pritchard - Morgan Stanley Michael Ryskin - Bank of America Steven Mah - TD Cowen Werner Lanthaler Welcome to our -- good morning. Good afternoon.

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
Accesswire22 August 2023 Sentiment: POSITIVE

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec: Significantly Undervalued, Or Value Trap?
Seeking Alpha05 April 2023 Sentiment: POSITIVE

A reader asked me to take a look at German company Evotec, which also has a dual listing on NASDAQ under symbol EVO. His question was whether I view the company as a value trap, or as a significantly undervalued stock that I would be open to investing in.

What type of business is Evotec SE?

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

What sector is Evotec SE in?

Evotec SE is in the Healthcare sector

What industry is Evotec SE in?

Evotec SE is in the Drug Manufacturers - Specialty & Generic industry

What country is Evotec SE from?

Evotec SE is headquartered in Germany

When did Evotec SE go public?

Evotec SE initial public offering (IPO) was on 05 February 2004

What is Evotec SE website?

https://www.evotec.com

Is Evotec SE in the S&P 500?

No, Evotec SE is not included in the S&P 500 index

Is Evotec SE in the NASDAQ 100?

No, Evotec SE is not included in the NASDAQ 100 index

Is Evotec SE in the Dow Jones?

No, Evotec SE is not included in the Dow Jones index

When does Evotec SE report earnings?

The next expected earnings date for Evotec SE is 29 August 2024